<DOC>
	<DOCNO>NCT00320190</DOCNO>
	<brief_summary>The purpose study compare efficacy dasatinib high-dose ( 800-mg ) imatinib participant chronic phase chronic myeloid leukemia achieve suboptimal response least 3 month monotherapy 400-mg imatinib . The safety treatment also evaluate .</brief_summary>
	<brief_title>Study Dasatinib Patients With Chronic Phase Chronic Myeloid Leukemia Suboptimal Response Imatinib</brief_title>
	<detailed_description>Participants randomize 2:1 dasatinib high-dose imatinib , respectively . Randomization stratify suboptimal response , define hematologic response less complete hematologic response least 3 month monotherapy 400-mg imatinib ; cytogenic response ( CgR ) less partial CgR ( PCgR ) least 6 month monotherapy 400-mg ; PCgR least 12 month monotherapy 400-mg imatinib ; le major molecular response complete CgR least 18 month monotherapy 400-mg imatinib . Participants receive either dasatinib imatinib 12 month disease progression , unacceptable toxicity , consent withdrawal , study discontinuation . After 12 month , confirm major molecular response still receive dasatinib , 100 mg , imatinib , 800 mg , eligible extend treatment additional 12 month . Participants permanently discontinue treatment 12 month consider treatment failure withdraw study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Chronic phase Ph^+ chronic myeloid leukemia ( CML ) demonstrate suboptimal response , define hematologic response less complete hematologic response least 3 month monotherapy imatinib , 400 mg ; cytogenic response ( CgR ) less partial CgR ( PCgR ) least 6 month monotherapy imatinib , 400 mg ; PCgR least 12 month monotherapy imatinib , 400 mg ; le major molecular response complete CgR least 18 month monotherapy imatinib , 400 mg . Either gender Age 18 year older Previous diagnosis accelerate phase blast crisis CML Uncontrolled significant cardiovascular disease History significant bleeding disorder unrelated CML Concurrent malignancy Intolerance imatinib , 400 mg Prior treatment imatinib dose high 400 mg Prior stem cell transplantation and/or highdose chemotherapy CML</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Chronic phase CML , suboptimal response treatment imatinib</keyword>
</DOC>